CVS Health Corp vs LYFT Inc — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.29B), while LYFT Inc trades at $16.2 (market cap $6.11B). The key difference: CVS Health Corp is far larger — about 18.4× LYFT Inc's market cap, and CVS Health Corp pays a 3.03% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and LYFT Inc for 47 Days on average.
| CVS | LYFT | |
|---|---|---|
Market Cap | $112.29B | $6.11B |
Volume | 7,763,676 | 13,504,560 |
Sector | Health | Technology |
52-Week High | $110.60 | $24.57 |
52-Week Low | $70.08 | $12.65 |
Typical Hold Time | 83 Days | 47 Days |
Enterprise Value | $174.64B | $5.57B |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
Lyft trades at $15.60, down 1.02% on the day, with a bullish technical outlook supported by moving averages despite recent earnings misses. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, while recent developments include European expansion and a $272.5M legal settlement. Cash flow has improved significantly, with operating cash flow reaching $1.17B in 2025.
Lyft presents a mixed investment case with attractive valuation metrics (P/E 2.35, P/S 0.96) but faces execution risks from recent earnings misses and competitive pressures. The 36.67% analyst buy rating and $18.07 consensus target suggest moderate upside potential, though regulatory concerns and market volatility remain key risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →